IOL Chemicals & Pharmaceuticals submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the National Stock Exchange of India Limited and BSE Limited on August 7, 2026. The filing, mandated under Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, details the company’s environmental, social, and governance performance. For FY26, the company reported a turnover of ₹2319.06 crore and a net worth of ₹1798.38 crore. The report highlights significant sustainability achievements, including 100% water neutrality and an 8.8% reduction in Scope 1 and Scope 2 greenhouse gas emission intensity compared to FY25, despite a 43% increase in API production volumes.

The BRSR forms part of the company’s Integrated Annual Report for FY26 and was assured by Intertek India Private Limited, which provided reasonable assurance on the disclosures. Abhay Raj Singh, Senior Vice President and Company Secretary, signed the submission. The report covers standalone operations, with the company maintaining one plant and three offices in India. Key business activities include the manufacturing of Active Pharma Ingredients and Intermediates, contributing 59.66% of turnover, and Specialty Chemicals, contributing 39.43%. Exports accounted for 24% of total turnover, serving markets in 70 countries.

Environmental Performance

IOL Chemicals & Pharmaceuticals reported total energy consumption of 2898 Tera Joules in FY26, comprising 2221.6 Tera Joules from renewable sources and 676.4 Tera Joules from non-renewable sources. Energy intensity per rupee of turnover was recorded at 0.000000125 Tera Joules. The company achieved 100% water neutrality, with total water withdrawal at 355,796 kilolitres and consumption at 355,796 kilolitres. A Zero Liquid Discharge process is implemented to treat, recycle, and reuse water in cooling towers.

Greenhouse gas emissions data reveals Total Scope 1 emissions of 60,731.8 metric tonnes of CO2 equivalent and Total Scope 2 emissions of 16,681.2 metric tonnes of CO2 equivalent. Total Scope 3 emissions were 85,528.6 metric tonnes of CO2 equivalent. The company noted that while absolute emissions rose due to production expansion, emission intensity decreased. Initiatives such as solar panel installation, waste-to-wealth projects, and supplier capacity building under the “Prayas” initiative contributed to these gains.

Social and Governance Highlights

The company employed 3,592 individuals as of the end of FY26, including 3,095 permanent employees. Women constituted 12.5% of the Board of Directors but held no positions in Key Management Personnel. The turnover rate for permanent employees was 16.00%. IOL Chemicals & Pharmaceuticals reported zero fatalities and one lost-time injury among employees during the year. The company maintains ISO 45001:2018 certification for occupational health and safety, covering 100% of its plants and offices.

Governance structures include a Corporate Social Responsibility Committee chaired by Rajender Mohan Malla. The company received two shareholder complaints in FY26, both resolved by year-end. No complaints were filed regarding sexual harassment, discrimination, or child labor. The company adheres to SA 8000:2014 social accountability standards and conducts regular training on human rights and ethical conduct for employees and value chain partners. Related party transactions accounted for 6.83% of purchases and 0.95% of investments, with no related-party sales or loans disclosed.

IOL Chemicals and Pharmaceuticals Limited has scheduled its 39th Annual General Meeting (AGM) for Wednesday, September 2, 2026, at 11:30 a.m. (IST). The meeting will be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM), allowing shareholders to participate remotely without physical presence. This procedural update accompanies the company’s recently filed Integrated Annual Report for FY26, which reported a standalone revenue rise to ₹2,319.06 crore and a profit after tax (PAT) increase to ₹137.72 crore.

AGM Agenda and Resolutions

Shareholders will transact both ordinary and special business during the meeting. Under ordinary business, members are asked to receive, consider, and adopt the Standalone and Consolidated Audited Financial Statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and Auditors.

The second ordinary item involves the reappointment of Mr. Kushal Kumar Rana as a Director. Mr. Rana retires by rotation and, being eligible, has offered himself for reappointment. He brings over 35 years of experience in the pharmaceutical industry, with expertise in manufacturing operations, quality systems, and regulatory compliance. Mr. Rana joined the company in 2005 and currently serves as Director (Works).

Special Business: Cost Auditor Remuneration

The primary special business item seeks shareholder approval to ratify the remuneration of the Cost Auditor for the financial year ending March 31, 2027. The Board of Directors, on the recommendation of the Audit Committee, appointed M/s Ramanath Iyer & Co., Cost Accountants, New Delhi (Firm Registration No. 000019), to conduct the audit of cost records for chemicals and bulk drugs.

The proposed remuneration is ₹2,00,000 (Rupees Two Lakh only), plus applicable taxes and reimbursement of out-of-pocket expenses actually incurred. This appointment complies with Section 148 of the Companies Act, 2013, read with the Companies (Audit and Auditors) Rules, 2014.

Voting and Participation Guidelines

Pursuant to Ministry of Corporate Affairs (MCA) circulars, the facility for appointing proxies is not available for this AGM. However, institutional shareholders may appoint authorized representatives under Section 113 of the Companies Act, 2013. Members attending via VC/OAVM will be counted toward the quorum under Section 103 of the Act.

Remote e-voting is facilitated by Central Depository Services (India) Limited (CDSL). The voting period opens on August 30, 2026, at 9:00 a.m. and closes on September 1, 2026, at 5:00 p.m. Only shareholders holding shares as of the record date, August 26, 2026, are eligible to vote. Those who cast their votes via remote e-voting prior to the meeting will not be eligible to vote again during the live session.

Shareholder Compliance and KYC

The Register of Members and Share Transfer Books will remain closed from August 27, 2026, to September 2, 2026. The company urges all shareholders to ensure their Know Your Client (KYC) details are updated to avoid delays in receiving dividends or communications.

For physical shareholders, KYC updates require submitting Form ISR-1 along with a cancelled cheque, PAN card copy, and address proof to the Registrar and Share Transfer Agent, Alankit Assignments Limited. Demat holders must update their details directly with their respective Depository Participants. The company also reminds members that unclaimed dividends held for seven consecutive years are liable to be transferred to the Investor Education and Protection Fund (IEPF).

Mr. Vinay Kohli, Partner at M/s K.K. Kapoor & Associates, Chartered Accountants, has been appointed as the scrutinizer for the e-voting process. Results will be declared within 48 hours of the AGM’s conclusion.